News

Using tears to test for self-reactive antibodies to help diagnose ocular myasthenia gravis (OMG) is more accurate than using blood samples, according to a study that found nearly all patients who tested negative for these antibodies in the blood had a positive result in tears. “Tear-based testing offers a…

Remegen’s telitacicept has been approved in China as an add-on treatment for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR) — that’s approximately 80% of all gMG patients, per the company. The decision, by the country’s National Medical Products Administration…

A rare form of myasthenia gravis that manifests in childhood and adolescence called juvenile myasthenia gravis (JMG) affects roughly 30 out of every 1 million children in the U.S., and may be more common than previously thought, a study estimates. The study also found that JMG is more common…

Vyvgart (efgartigimod alfa-fcab) may be safer and more effective than intravenous immunoglobulin (IVIG) therapy in elderly people with generalized myasthenia gravis (gMG), a study shows. In elderly Chinese patients with gMG who were positive for antibodies targeting the acetylcholine receptor (AChR), Vyvgart eased symptoms after four and…

Enrollment is open in an investigator-initiated clinical trial to evaluate cell therapy NKX019 in people with myasthenia gravis (MG). Nkarta, the therapy’s developer, made the announcement in a company press release. Researchers at the University of California, Irvine, and the University of Kansas Medical Center are leading the…

Robotic thymectomy is a safe and effective treatment for people with myasthenia gravis (MG), including patient groups that have historically showed poorer outcomes, a study found. Five years after undergoing robotic thymectomy, a minimally invasive surgery to remove the thymus gland, 84% of patients saw their MG…

Kyverna Therapeutics is planning to launch a Phase 3 clinical trial testing its experimental cell therapy KYV-101 in people with myasthenia gravis (MG). The announcement follows an end-of-Phase 2 meeting between Kyverna and the U.S. Food and Drug Administration (FDA). According to the company, the FDA has…

Cartesian Therapeutics is gearing up for two clinical trials of its cell therapy Descartes-08: the first, a Phase 3 study, will enroll adults with myasthenia gravis (MG), while the second, a Phase 2 basket trial, will test the treatment candidate in children with juvenile MG and other…

Japan’s drug regulatory agency has authorized two new administration methods for Rystiggo (rozanolixizumab) — an approved treatment for generalized myasthenia gravis (gMG) — that people with the chronic autoimmune condition can use at home. These approvals, by the Pharmaceuticals and Medical Devices Agency, or PMDA, will allow gMG…

The recently approved prefilled syringe formulation of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that offers the possibility of self-administration is now available in the U.S. for eligible adults with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChRs). These ready-to-use syringes are intended to be…